Predicting phenotype in steroid 21-hydroxylase deficiency? Comprehensive genotyping in 155 unrelated, well defined patients from southern Germany

被引:297
作者
Krone, N [1 ]
Braun, A [1 ]
Roscher, AA [1 ]
Knorr, D [1 ]
Schwarz, HP [1 ]
机构
[1] Univ Munich, Childrens Hosp, D-80337 Munich, Germany
关键词
D O I
10.1210/jc.85.3.1059
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Congenital adrenal hyperplasia (CAH) is a group of autosomal recessive disorders. CAH is most often caused by deficiency of steroid 21-hydroxylase. The frequency of CYP21-inactivating mutations and the genotype-phenotype relationship were characterized in 155 well defined unrelated CAH patients. We were able to elucidate 306 of 310 disease-causing alleles (diagnostic sensitivity, 98.7%). The most frequent mutation was the intron 2 splice site mutation (30.3%), followed by gene deletions (20.3%), the I172N mutation (19.7%) and large gene conversions (7.1%). Five point mutations were detected that have not been described in other CAH cohorts. Genotypes were categorized in 4 mutation groups (null, A, B, and C) according to their predicted functional consequences and compared to the clinical phenotype. The positive predictive value for null mutations (ppv(null)) was 100%, as all patients with these mutations had a salt wasting phenotype. In mutation group A (intron 2 splice site mutation in homozygous or heterozygous form with a null mutation), the ppv(A) to manifest with salt-wasting CAH was 90%. In group B predicted to result in simple virilizing CAH (I172Nin homozygous or compound heterozygous form with a more severe mutation), ppv(B) was 74%. In group C (P30L, V281L, P453S in homozygous or compound heterozygous form with a more severe mutation), ppv(C) was 64.7% to exhibit the nonclassical form of CAH, but 90% when excluding the P30L mutation. Thus, in general, a good genotype-phenotype relationship is shown in patients with either the severest or the mildest mutations. A considerable degree of divergence is observed within mutation groups of intermediate severity. As yet undefined factors modifying al-hydroxylase gene expression and steroid hormone action are likely to account for these differences in phenotypic expression.
引用
收藏
页码:1059 / 1065
页数:7
相关论文
共 35 条
[1]   SCREENING OF CYP21 GENE-MUTATIONS IN 129 FRENCH PATIENTS AFFECTED BY STEROID 21-HYDROXYLASE DEFICIENCY [J].
BARBAT, B ;
BOGYO, A ;
RAUXDEMAY, MC ;
KUTTENN, F ;
BOUE, J ;
SIMONBOUY, B ;
SERRE, JL ;
BOUE, A ;
MORNET, E .
HUMAN MUTATION, 1995, 5 (02) :126-130
[2]   Study of a kindred with classic congenital adrenal hyperplasia: Diagnostic challenge due to phenotypic variance [J].
Chin, DS ;
Speiser, PW ;
Imperato-McGinley, J ;
Dixit, N ;
Uli, N ;
David, R ;
Oberfield, SE .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1998, 83 (06) :1940-1945
[3]   The -104G nucleotide of the human CYP21 gene is important for CYP21 transcription activity and protein interaction [J].
Chin, KK ;
Chang, SF .
NUCLEIC ACIDS RESEARCH, 1998, 26 (08) :1959-1964
[4]   THE HUMAN-COMPLEMENT C4B STEROID 21-HYDROXYLASE (CYP21) AND COMPLEMENT C4A/21-HYDROXYLASE PSEUDOGENE (CYP21P) INTERGENIC SEQUENCES - COMPARISON AND IDENTIFICATION OF POSSIBLE REGULATORY ELEMENTS [J].
DONOHOUE, PA ;
COLLINS, MM .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1992, 186 (01) :256-262
[5]  
Donohoue PA, 1995, METABOLIC BASIS INHE, V7, P2929
[6]   ANALYSIS OF STEROID 21-HYDROXYLASE GENE-MUTATIONS IN THE SPANISH POPULATION [J].
EZQUIETA, B ;
OLIVER, A ;
GRACIA, R ;
GANCEDO, PG .
HUMAN GENETICS, 1995, 96 (02) :198-204
[7]  
HIGASHI Y, 1988, AM J HUM GENET, V42, P17
[8]   COMPLETE NUCLEOTIDE-SEQUENCE OF 2 STEROID 21-HYDROXYLASE GENES TANDEMLY ARRANGED IN HUMAN-CHROMOSOME - A PSEUDOGENE AND A GENUINE GENE [J].
HIGASHI, Y ;
YOSHIOKA, H ;
YAMANE, M ;
GOTOH, O ;
FUJIIKURIYAMA, Y .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1986, 83 (09) :2841-2845
[9]   Population-wide evaluation of disease manifestation in relation to molecular genotype in steroid 21-hydroxylase (CYP21) deficiency: Good correlation in a well defined population [J].
Jaaskelainen, J ;
Levo, A ;
Voutilainen, R ;
Partanen, J .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1997, 82 (10) :3293-3297
[10]  
Krone N, 1999, Hum Mutat, V14, P90, DOI 10.1002/(SICI)1098-1004(1999)14:1<90::AID-HUMU20>3.0.CO